SCHEMBL3743138

SCHEMBL3743138

C[C]1CCNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2499913 0.81
SCHEMBL15711119 0.73
SCHEMBL4060406 0.71
SCHEMBL12616408 0.68
SCHEMBL14084004 0.65
SCHEMBL9492206 0.65
SCHEMBL22746031 0.65
SCHEMBL11981382 0.62 HTR2C (0.44)
SCHEMBL13228781 0.62 PNMT (0.31)
SCHEMBL22041460 0.62 OPRM1 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024041573-A1 FUSED MULTI-HETEROCYCLIC COMPOUNDS AS KRAS G12D MODULATORS AND USES THEREOF ZAI LAB (SHANGHAI) CO., LTD. (CN) 2024-02-29 WO disclosed
WO-2023137406-A1 HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND METHODS OF USING SAME SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) 2023-07-20 WO disclosed
CN-113272297-A Pyrazole derivatives as H4 antagonist compounds 赫普泰雅治疗有限公司 2021-08-17 CN disclosed
EP-3802500-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2021-04-14 EP disclosed
EP-3077387-A1 BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER Janssen Pharmaceutica, N.V. (BE) 2016-10-12 EP disclosed
US-20160257686-A1 Purinone Derivatives as Tyrosine Kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2016-09-08 US disclosed
WO-2015084606-A1 BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER JANSSEN PHARMACEUTICA NV (BE) 2015-06-11 WO disclosed
US-20140142099-A1 Purinone Derivatives as Tyrosine Kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2014-05-22 US disclosed
US-8372859-B2 CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups Merck, Sharp & Dohme Corp. (US) 2013-02-12 US disclosed
US-8247442-B2 Benzenesulfonamide compounds and their use PURDUE PHARMA L.P. (US) 2012-08-21 US disclosed
US-20100292263-A1 CGRP RECEPTOR ANTAGONISTS WITH TERTIARY AMIDE, SULFONAMIDE, CARBAMITE AND UREA GROUPS MERCK SHARP & DOHME LLC 2010-11-18 US disclosed
US-20090239910-A1 Benzenesulfonamide Compounds and Their Use EURO-CELTIQUE S.A. (LU) 2009-09-24 US disclosed
EP-2007733-A1 AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2008-12-31 EP disclosed
EP-1874727-A1 NEW MUSCARINIC RECEPTOR ANTAGONISTS AstraZeneca AB (SE) 2008-01-09 EP disclosed
WO-2007113596-A1 AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-10-11 WO disclosed
WO-2007110449-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE EURO-CELTIQUE S.A. (LU) 2007-10-04 WO disclosed
WO-2006112778-A1 NEW MUSCARINIC RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2006-10-26 WO disclosed